Abstract： Objective： To observe the therapeutic effects of Niaoduqing Granules combined with Febuxostat in patients with renal damage due to hyperuricemia. Methods： A total of 160 patients with renal damage due to hyperuricemia treated at Zhuji Sixth People's Hospital from July 2022 to July 2024 were selected and divided into a study group and a control group，with 80 cases in each group，using a random number table method. The study group was treated with Niaoduqing Granules combined with Febuxostat，while the control group was treated with Febuxostat alone. Clinical effects and the incidence of adverse reactions were compared between the two groups. Renal function indicators [uric acid （UA），serum creatinine （SCr），and serum cystatin C （Cys C）]，vascular endothelial function [serum endothelin-1 （ET-1） and nitric oxide （NO）]， and inflammatory factors [high-sensitivity C-reactive protein （hs-CRP），interleukin-6 （IL-6），and tumor necrosis factor-α （TNF-α）] levels were compared before and after treatment. Results：The total effective rate of clinical efficacy in the study group was 91.25%（73/80），compared to 77.50%（62/80） in the control group， with difference being significant （P＜0.05）. After two months of treatment， Cys C，SCr，and UA levels in both groups were decreased compared to those before treatment （P＜0.05），with the study group achieving lower levels than the control group （P＜0.05）. After two months of treatment，ET-1 levels in both groups were decreased （P＜0.05），while NO levels were increased （P＜0.05）. The study group had lower ET-1 levels and higher NO levels than the control group （P＜0.05）. After two months of treatment，hs-CRP，IL-6，and TNF-α levels in both groups were decreased compared to those before treatment （P＜0.05）， with the study group achieving lower levels than the control group （P＜0.05）. The incidence of adverse reactions was 10.00%（8/80） in the control group and 6.25%（5/80） in the study group， with no significant difference between the two groups （P＞0.05）. Conclusion： The combination of Niaoduqing Granules and Febuxostat can improve clinical efficacy in patients with renal damage due to hyperuricemia， enhance renal function and vascular endothelial function， and reduce inflammatory responses，with high safety.